Cassava Sciences $SAVA Stock Up 15% After Trading Halt, No Manipulation of Data

  • Post category:Biotechnology
  • Reading time:7 mins read
Get Email Alerts and Follow Us:

SAVA stock surged more than 15% higher in morning trade on December 21, 2021, after a science journal said there was no evidence any data was manipulated by the company. A trading halt was placed on the stock while the news was released and disseminated to the public.

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

AUSTIN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc., (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper authored by the Company and its scientific collaborators. Neuroscience is a prestigious academic journal whose mission is to report “significant, new and carefully confirmed findings with full experimental details.”

  1. Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.”
  2. Clearance Is From A Neutral Party Who Is Expert In The Field

“Another science journal has cleared us of allegations,” said Remi Barbier, President & CEO. “This clearance is from an independent third party who is neutral and expert in the field. This reinforces my conviction that false and misleading allegations of scientific misconduct being made against us are simply designed to enrich those making them. People who seek to profit from false allegations may not comprehend the harm they are causing the Alzheimer’s community, or perhaps they simply don’t care. Leaving a trail of destruction in their wake in the quest for profit, with little concern for patients or their caregivers, is a twisted form of money-making and the opposite of what people with dementia deserve.”

In August 2021, a law firm representing admitted short sellers submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) that alleges, among other things, data manipulation in scientific articles authored by Cassava scientists, including the 2005 Neuroscience article. In response to this and similar online allegations, Neuroscience requested raw data for the 2005 article, including images of original, uncropped Western blots. Having completed a careful examination of the data, on December 20, 2021, Neuroscience published on-line the following Editorial Note:

“In response to allegations of data manipulation in an article published in Neuroscience Vol 135, Issue 1, 2005, Pages 247-261, and following COPE (Committee on Publication Ethics) guidelines, the journal asked the authors for images of the original, uncropped Western blots from this study. After careful examination of these original material, Neuroscience found no evidence of manipulation of the Western blot data or other figures of this publication.”

In November 2021, Cassava Sciences reported that a different science journal (i.e., Journal of Neuroscience) also found no evidence to support allegations of data manipulation in an article it published in 2012. On December 17, 2021, the Journal of Neuroscience issued a subsequent Expression of Concern while maintaining its earlier clearance, pending the outcome of a different investigation by an academic party into allegations.

Additionally, in October 2021, a respected academic researcher, PhD in Molecular Biology, published on a website4 his detailed examination of allegations made in a supplement to the Citizen Petition. The researcher, whose laboratory routinely runs a thousand or more Western blots per year, concluded that claims of scientific misconduct levied against Cassava Sciences and its collaborator were “borderline ridiculous”5, noting that “several of the examples shown as evidence of data manipulation [in the Citizen Petition] support the opposite [conclusion].”6 Cassava Sciences has not provided any form of compensation to the academic researcher and has no control over the contents of this website or its author.

Cassava Sciences is grateful for journal editors and independent reviewers who have taken time from busy research schedules to address the allegations.

Journal of Neuroscience publishes expression of concern on Cassava article

On December 17, 2021, The “Journal of Neuroscience” is publishing an Expression of Concern for the article JNeurosci 2012;32:9773-9784 which appeared in the July 18, 2012 issue. “The editors have been made aware of concerns about Western blots in this study, including those published with the article’s erratum. These and other concerns are currently under investigation by the academic authorities at the City University of New York, CUNY. JNeurosci will await the outcome of that investigation before taking further action,” a notice posted by the Journal stated. Previously, on November 4, Cassava Sciences announced that it has been informed by the “Journal of Neuroscience” that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer’s disease. “The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the company’s lead drug candidate for the proposed treatment of Alzheimer’s disease,” the company previously stated. Source:


On December 19, 2021, Rara Koko Good Vibes Man gave his opinion on SAVA stock.

📈 SAVA Stock Technical Analysis

Sava Stock

Both the long and short term trends are negative; However, with the price action on December 21, 2021, SAVA is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 98% of 257 stocks in the same industry. SAVA is currently trading in the lower part of its 52 week range. The S&P500 Index however is trading in the upper part of its 52 week range, so SAVA is lagging the market. There is a support zone ranging from 36.76 to 36.78. This zone is formed by a combination of multiple trend lines in multiple time frames. There is resistance at 72.15 from a trend line in the daily time frame. There is also resistance at 89.72 from a horizontal line in the daily time frame. SAVA has a poor technical rating and the quality of the setup is also only medium at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when SAVA stock is a good entry.

Get Email Alerts and Follow Us: